BioOutsource Launches Flagship Reverse Signaling Apoptosis Bioassay

| Print |
Monday, 24 March 2014 10:00 (UTC + 1)

BioOutsource Logo

Presents webinar on improving speed to market for Biosimilars

Glasgow, Scotland, UK and Boston, Mass, USA, March 24, 2014 / B3C newswire / – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and BioSimilar characterisation for the biopharmaceutical industry, today announced the launch of the flagship Reverse Signaling Apoptosis Bioassay,  adding to the extensive range of characterisation services offered by the company. The assay is a critical method, required by the regulators for licensure of Humira and Remicade BioSimilars.

The Reverse Signaling Apoptosis bioassay replicates a critical component of TNF-Alpha biology whereby membrane bound TNF-Alpha acts as a receptor, mediating a negative feedback system following binding by the TNF2 receptor. This results in cytokine suppression and the induction of apoptosis in TNF-Alpha producing cells, thereby dampening the elevated immune response.   

BioOutsource CSO, Dr Daniel Galbraith commented; “We are delighted to be the first to bring the Reverse Signaling Apoptosis Assay to market. It completes our extensive range of characterisation testing capabilities and ensures BioOutsource now support the full biological characterisation of Humira and Remicade BioSimilars.”

In addition, BioOutsource also announced that Dr. Galbraith will shortly present a webinar on How Biological Characterisation is improving speed to market for BioSimilars.

Dr. Galbraith commented “The webinar will present how the biological characterisation of BioSimilar Monoclonal Antibodies plays a critical role in the development pathway for Biosimilars.  I am looking forward to presenting our extensive experience in this area and engaging with thought leaders in the industry in the Q&A section”.  The webinar is being hosted in partnership with Business Review Webinars on 27th March 2014 at 3pm GMT.

BioOutsource has also announced that it will shortly be exhibiting at CHI’s Biotherapeutics Analytical Summit in Baltimore, USA on 24-28th March 2014, followed by Informa’s, BioProcessing International European Summit in Prague, Czech Republic on 2-3rd April 2014.

For more information on our upcoming conferences and events please follow this link.

 
About BioOutsource Ltd
BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of Biologics, Vaccines & BioSimilars throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry’s increasingly preferred testing partner. We understand the importance of our service to support our client’s critical testing requirements and as a result, continually strive to provide a world class service globally. 


Contact

Gemma Fulton
Sales & Marketing Associate
BioOutsource, Ltd.
+ 44 (0) 141 948 1291
This e-mail address is being protected from spambots. You need JavaScript enabled to view it